KR20120028882A - Ｍｅｋ 억제제로서의 헤테로시클릭 화합물 - Google Patents
Ｍｅｋ 억제제로서의 헤테로시클릭 화합물 Download PDFInfo
- Publication number
- KR20120028882A KR20120028882A KR1020117027486A KR20117027486A KR20120028882A KR 20120028882 A KR20120028882 A KR 20120028882A KR 1020117027486 A KR1020117027486 A KR 1020117027486A KR 20117027486 A KR20117027486 A KR 20117027486A KR 20120028882 A KR20120028882 A KR 20120028882A
- Authority
- KR
- South Korea
- Prior art keywords
- fluoro
- phenylamino
- tetrahydro
- oxo
- carboxylic acid
- Prior art date
Links
- YHBGTHUWURYKGA-UHFFFAOYSA-N CC(C(N(CCC1)C1=C1NC2=O)=O)=C1N2c(ccc(Br)c1)c1F Chemical compound CC(C(N(CCC1)C1=C1NC2=O)=O)=C1N2c(ccc(Br)c1)c1F YHBGTHUWURYKGA-UHFFFAOYSA-N 0.000 description 1
- OZHMGVCYJWVQMN-UHFFFAOYSA-N CC1(C)OC(CONC(C(C(Nc(c(F)c2)ccc2I)=C2Cl)=C(CCC3)N3C2=O)=O)CO1 Chemical compound CC1(C)OC(CONC(C(C(Nc(c(F)c2)ccc2I)=C2Cl)=C(CCC3)N3C2=O)=O)CO1 OZHMGVCYJWVQMN-UHFFFAOYSA-N 0.000 description 1
- 0 CCII(N)I[*+]C(C1)C([C@]2O[C@]2*)=I(CCC2)*2C1O Chemical compound CCII(N)I[*+]C(C1)C([C@]2O[C@]2*)=I(CCC2)*2C1O 0.000 description 1
- IMRIEOLYRJFLJW-UHFFFAOYSA-N CCOC(C(C(Nc(ccc(C(F)(F)F)c1)c1F)=C1)=C(CCC2)N2C1=O)=O Chemical compound CCOC(C(C(Nc(ccc(C(F)(F)F)c1)c1F)=C1)=C(CCC2)N2C1=O)=O IMRIEOLYRJFLJW-UHFFFAOYSA-N 0.000 description 1
- NWSKLPDPUFBJDU-UHFFFAOYSA-N CCOC(C(C(O)=C1)=C(CCC2)N2C1=O)=O Chemical compound CCOC(C(C(O)=C1)=C(CCC2)N2C1=O)=O NWSKLPDPUFBJDU-UHFFFAOYSA-N 0.000 description 1
- QDNBHRSXDYSMAV-UHFFFAOYSA-N CCONC(C(C(Nc(ccc(Br)c1)c1F)=C1F)=C(CCC2)N2C1=O)=O Chemical compound CCONC(C(C(Nc(ccc(Br)c1)c1F)=C1F)=C(CCC2)N2C1=O)=O QDNBHRSXDYSMAV-UHFFFAOYSA-N 0.000 description 1
- VIYVUYZKPXPEQI-UHFFFAOYSA-N COCOCC(C(C(Nc(ccc(Br)c1)c1F)=C1F)=C(CCC2)N2C1=O)=O Chemical compound COCOCC(C(C(Nc(ccc(Br)c1)c1F)=C1F)=C(CCC2)N2C1=O)=O VIYVUYZKPXPEQI-UHFFFAOYSA-N 0.000 description 1
- AHQDFZGPKFZQPJ-UHFFFAOYSA-N COc(cc1F)ccc1NC(C(C(NOCC1CC1)=O)=C1N2CCC1)=CC2=O Chemical compound COc(cc1F)ccc1NC(C(C(NOCC1CC1)=O)=C1N2CCC1)=CC2=O AHQDFZGPKFZQPJ-UHFFFAOYSA-N 0.000 description 1
- NMSDBKZPLWVPMI-UHFFFAOYSA-N CS(N(C(C(N1c(ccc(Br)c2)c2F)=C2)=C(CCC3)N3C2=O)C1=O)(=O)=O Chemical compound CS(N(C(C(N1c(ccc(Br)c2)c2F)=C2)=C(CCC3)N3C2=O)C1=O)(=O)=O NMSDBKZPLWVPMI-UHFFFAOYSA-N 0.000 description 1
- ZTWXXAJLBBXNSW-UHFFFAOYSA-N Cc(cc(cc1)Br)c1NC(C(C(O)=O)=C(CCC1)N1C1=O)=C1F Chemical compound Cc(cc(cc1)Br)c1NC(C(C(O)=O)=C(CCC1)N1C1=O)=C1F ZTWXXAJLBBXNSW-UHFFFAOYSA-N 0.000 description 1
- UDUJLFLJBHPZEL-UHFFFAOYSA-N O=C(C(C(Nc(ccc(C(F)(F)F)c1)c1F)=C1)=C(CCC2)N2C1=O)NOCC1CC1 Chemical compound O=C(C(C(Nc(ccc(C(F)(F)F)c1)c1F)=C1)=C(CCC2)N2C1=O)NOCC1CC1 UDUJLFLJBHPZEL-UHFFFAOYSA-N 0.000 description 1
- NORXNBYGOCUEAV-UHFFFAOYSA-N O=C(C(C(Nc1ccc(C(F)(F)F)cc1F)=C1F)=C(CCC2)N2C1=O)NOCC1CC1 Chemical compound O=C(C(C(Nc1ccc(C(F)(F)F)cc1F)=C1F)=C(CCC2)N2C1=O)NOCC1CC1 NORXNBYGOCUEAV-UHFFFAOYSA-N 0.000 description 1
- QYXSFNOCUBIFNS-UHFFFAOYSA-N OCC(C(C(Nc(ccc(Br)c1)c1F)=C1F)=C(CCC2)N2C1=O)=O Chemical compound OCC(C(C(Nc(ccc(Br)c1)c1F)=C1F)=C(CCC2)N2C1=O)=O QYXSFNOCUBIFNS-UHFFFAOYSA-N 0.000 description 1
- IPROFDRPBZNCIY-UHFFFAOYSA-N OCC(CONC(C(C(Nc(c(F)c1)ccc1I)=C1Cl)=C(CCC2)N2C1=O)=O)O Chemical compound OCC(CONC(C(C(Nc(c(F)c1)ccc1I)=C1Cl)=C(CCC2)N2C1=O)=O)O IPROFDRPBZNCIY-UHFFFAOYSA-N 0.000 description 1
- APTCJGQUVQBIJN-UHFFFAOYSA-N OCCCNC(C(C(Nc(ccc(Br)c1)c1F)=C1)=C(CCC2)N2C1=O)=O Chemical compound OCCCNC(C(C(Nc(ccc(Br)c1)c1F)=C1)=C(CCC2)N2C1=O)=O APTCJGQUVQBIJN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2009/054717 WO2010121646A1 (en) | 2009-04-21 | 2009-04-21 | Heterocyclic compounds as mek inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20120028882A true KR20120028882A (ko) | 2012-03-23 |
Family
ID=43010696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117027486A KR20120028882A (ko) | 2009-04-21 | 2009-04-21 | Ｍｅｋ 억제제로서의 헤테로시클릭 화합물 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2421612A1 (zh) |
| JP (1) | JP2012524114A (zh) |
| KR (1) | KR20120028882A (zh) |
| CN (1) | CN102458580A (zh) |
| AU (1) | AU2009344690A1 (zh) |
| BR (1) | BRPI0925050A2 (zh) |
| CA (1) | CA2761108A1 (zh) |
| EA (1) | EA201101533A1 (zh) |
| MX (1) | MX2011011083A (zh) |
| WO (1) | WO2010121646A1 (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2456966T3 (es) | 2007-11-12 | 2014-04-24 | Takeda Pharmaceutical Company Limited | Inhibidores de MAPK/ERK cinasa |
| PE20121471A1 (es) * | 2009-11-04 | 2012-11-01 | Novartis Ag | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek |
| MX2013014398A (es) * | 2011-06-09 | 2014-03-21 | Novartis Ag | Derivados de sulfonamida heterociclicos. |
| GB201201332D0 (en) | 2012-01-26 | 2012-03-14 | Imp Innovations Ltd | Method |
| JP6431770B2 (ja) | 2012-03-14 | 2018-11-28 | ルピン・リミテッド | Ｍｅｋインヒビターとしてのヘテロシクリル化合物 |
| EP3702351B1 (en) | 2012-10-19 | 2023-11-22 | Array Biopharma, Inc. | Formulation comprising a mek inhibitor |
| WO2016009306A1 (en) | 2014-07-15 | 2016-01-21 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
| CN105384754B (zh) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| WO2016035008A1 (en) | 2014-09-04 | 2016-03-10 | Lupin Limited | Pyridopyrimidine derivatives as mek inhibitors |
| CN108640916A (zh) * | 2018-06-07 | 2018-10-12 | 广东药科大学 | 一类具有抗癌活性的硫代吲嗪类化合物及其衍生物 |
| CN109761977B (zh) * | 2019-03-05 | 2020-07-17 | 江西省药品检验检测研究院 | 一种黄精生物碱c及其制备方法与应用 |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| ES2456966T3 (es) * | 2007-11-12 | 2014-04-24 | Takeda Pharmaceutical Company Limited | Inhibidores de MAPK/ERK cinasa |
-
2009
- 2009-04-21 CN CN2009801598607A patent/CN102458580A/zh active Pending
- 2009-04-21 BR BRPI0925050-6A patent/BRPI0925050A2/pt not_active IP Right Cessation
- 2009-04-21 MX MX2011011083A patent/MX2011011083A/es not_active Application Discontinuation
- 2009-04-21 AU AU2009344690A patent/AU2009344690A1/en not_active Abandoned
- 2009-04-21 EP EP09779322A patent/EP2421612A1/en not_active Withdrawn
- 2009-04-21 EA EA201101533A patent/EA201101533A1/ru unknown
- 2009-04-21 JP JP2012506346A patent/JP2012524114A/ja active Pending
- 2009-04-21 KR KR1020117027486A patent/KR20120028882A/ko not_active Application Discontinuation
- 2009-04-21 WO PCT/EP2009/054717 patent/WO2010121646A1/en active Application Filing
- 2009-04-21 CA CA2761108A patent/CA2761108A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0925050A2 (pt) | 2015-08-04 |
| EA201101533A1 (ru) | 2012-05-30 |
| JP2012524114A (ja) | 2012-10-11 |
| CA2761108A1 (en) | 2010-10-28 |
| MX2011011083A (es) | 2011-11-04 |
| CN102458580A (zh) | 2012-05-16 |
| WO2010121646A1 (en) | 2010-10-28 |
| AU2009344690A1 (en) | 2011-10-27 |
| EP2421612A1 (en) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20120028882A (ko) | Ｍｅｋ 억제제로서의 헤테로시클릭 화합물 | |
| JP5466767B2 (ja) | Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体 | |
| EP1900729A1 (en) | Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors | |
| NZ588069A (en) | Hydroxamate-based inhibitors of deacetylases b | |
| US20090275606A1 (en) | Heterocyclic Compounds as MEK Inhibitors | |
| JP5456908B2 (ja) | ヘテロ環式スルホンアミド誘導体 | |
| AU2012265844A1 (en) | Heterocyclic sulfonamide derivatives | |
| US8470878B2 (en) | Heterocyclic sulfonamide derivatives | |
| Subramanya | 2, Patent Application Publication to, Pub. No.: US 2009/0275606 A1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |